{"DataElement":{"publicId":"6733007","version":"1","preferredName":"Hemophilia Emicizumab Therapy Coagulation Factor VIII Inhibitor Nijmegen-Bethesda Assay Bovine Reagent Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of haemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by  coagulation factor VIII (FVIII); FVIII is missing in HA patients._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._A class of substances that binds to and inhibits the function or activity of a target._A modification of the Bethesda Assay where the pH and the protein concentration of the test mixture is further standardized, such that the factor VIII coagulant activity (FVIII:C) in the test mixture is less prone to artifactual deterioration and the test has improved specificity._Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance._A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"6733006v1.0:6732978v1.0","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6733006","version":"1","preferredName":"Hemophilia Emicizumab Therapeutic Procedure Coagulation Factor VIII Inhibitor Nijmegen-Bethesda Assay","preferredDefinition":"Group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots._A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of haemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by  coagulation factor VIII (FVIII); FVIII is missing in HA patients._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._A class of substances that binds to and inhibits the function or activity of a target._A modification of the Bethesda Assay where the pH and the protein concentration of the test mixture is further standardized, such that the factor VIII coagulant activity (FVIII:C) in the test mixture is less prone to artifactual deterioration and the test has improved specificity.","longName":"Hemo_Emic_Ther_Coag_Inhi_Nijm","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"2412140","version":"1","preferredName":"Hemophilia","preferredDefinition":"Group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots.","longName":"C3093","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophilia","conceptCode":"C3093","definition":"A deficiency or abnormality of a blood coagulation factor characterized by the tendency to hemorrhage. Hemophilia is typically a hereditary disorder but, rarely, may be acquired. Inherited coagulation factor-deficient hemophilias include hemophilia A or classic hemophilia (hereditary factor VIII deficiency) hemophilia B or Christmas disease (hereditary factor IX deficiency), and hemophilia C (hereditary factor XI deficiency). Factor VIII inhibitors may occur spontaneously as autoantibodies, resulting in acquired hemophilia known as acquired factor VIII deficiency. Approximately 10% of patients with acquired hemophilia have an underlying malignancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"01D4D496-BB15-3A9F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-28","modifiedBy":"ONEDATA","dateModified":"2005-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6733004","version":"1","preferredName":"Emicizumab Therapeutic Procedure Coagulation Factor VIII Inhibitor Nijmegen-Bethesda Assay","preferredDefinition":"A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of haemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by  coagulation factor VIII (FVIII); FVIII is missing in HA patients.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.:A class of substances that binds to and inhibits the function or activity of a target.:A modification of the Bethesda Assay where the pH and the protein concentration of the test mixture is further standardized, such that the factor VIII coagulant activity (FVIII:C) in the test mixture is less prone to artifactual deterioration and the test has improved specificity.","longName":"6733004v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emicizumab","conceptCode":"C159541","definition":"A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Coagulation Factor VIII","conceptCode":"C16571","definition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inhibitor","conceptCode":"C154898","definition":"A class of substances that binds to and inhibits the function or activity of a target.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Nijmegen-Bethesda Assay","conceptCode":"C159544","definition":"A modification of the Bethesda Assay where the pH and the protein concentration of the test mixture is further standardized, such that the factor VIII coagulant activity (FVIII:C) in the test mixture is less prone to artifactual deterioration and the test has improved specificity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87714E4A-4B42-19C7-E053-F662850A2C4A","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87714E4A-4B53-19C7-E053-F662850A2C4A","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732978","version":"1","preferredName":"Bovine species Reagent Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"No Value Exists_Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance._A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"6732978v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732977","version":"1","preferredName":"Bovine species Reagent Chromogenic Substrate Clotting Factor Assay","preferredDefinition":"No Value Exists:Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance.:A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","longName":"L-80100:C802:C159552","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bovine species","conceptCode":"L-80100","definition":"No Value Exists","evsSource":"SNOMED-CT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Reagent","conceptCode":"C802","definition":"Any natural or synthetic substance used in a chemical or biological reaction in order to produce, identify, or measure another substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chromogenic Substrate Clotting Factor Assay","conceptCode":"C159552","definition":"A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87708EBF-046E-43ED-E053-F662850A03FD","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87708EBF-047F-43ED-E053-F662850A03FD","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Hemophilia Emicizumab Therapy Coagulation Factor VIII Inhibitor Nijmegen-Bethesda Assay Bovine Reagent Chromogenic Substrate Clotting Factor Assay does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Hemophilia Emicizumab Therapy Coagulation Factor VIII Inhibitor Nijmegen-Bethesda Assay Bovine Reagent Chromogenic Substrate Clotting Factor Assay does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"877096E5-F6D6-5CB0-E053-F662850A9DA5","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}